This guideline covers the care and support of adults receiving social care in their own homes, residential care and community settings. It aims to help people understand what care they can expect and to improve their experience by supporting them to make decisions about their care.
This guideline covers services for children, young people and adults with a learning disability (or autism and a learning disability) and behaviour that challenges. It aims to promote a lifelong approach to supporting people and their families and carers, focusing on prevention and early intervention and minimising inpatient admissions.
This guideline covers care and support for adults with learning disabilities as they grow older. It covers identifying changing needs, planning for the future, and delivering services including health, social care and housing. It aims to support people to access the services they need as they get older.
This guideline covers recognising and responding to abuse and neglect in children and young people aged under 18. It covers physical, sexual and emotional abuse, and neglect. The guideline aims to help anyone whose work brings them into contact with children and young people to spot signs of abuse and neglect and to know how to respond. It also supports practitioners who carry out assessments and provide early help and interventions to children, young people, parents and carers.
This guideline covers referral and assessment for intermediate care and how to deliver the service. Intermediate care is a multidisciplinary service that helps people to be as independent as possible. It provides support and rehabilitation to people at risk of hospital admission or who have been in hospital. It aims to ensure people transfer from hospital to the community in a timely way and to prevent unnecessary admissions to hospitals and residential care.
This guideline covers medicines support for adults (aged 18 and over) who are receiving social care in the community. It aims to ensure that people who receive social care are supported to take and look after their medicines effectively and safely at home. It gives advice on assessing if people need help with managing their medicines, who should provide medicines support and how health and social care staff should work together.
This guideline covers decision-making in people 16 years and over who may lack capacity now or in the future. It aims to help health and social care practitioners support people to make their own decisions where they have the capacity to do so. It also helps practitioners to keep people who lack capacity at the centre of the decision-making process.
Evidence-based recommendations on eliglustat (Cerdelga) for treating type 1 Gaucher disease in adults
Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia (XLH) in children and young people
Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in adults and children
Evidence-based recommendation on Strimvelis for adenosine deaminase deficiency–severe combined immunodeficiency (ADA–SCID)
Evidence-based recommendations on migalastat (Galafold) for treating Fabry disease in people over 16
Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy
Evidence-based recommendations on inotersen (Tegsedi) for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis
Evidence-based recommendations on voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophies (confirmed biallelic RPE65 gene mutations)
NICE was unable to make a recommendation about the use in the NHS of bevacizumab for epidermal growth factor receptor mutation-positive non-small-cell lung
NICE is unable to make a recommendation about the use of ibrutinib with bendamustine and rituximab for relapsed or refractory chronic lymphocytic leukaemia
Evidence-based recommendations on obeticholic acid (Ocaliva) for treating primary biliary cholangitis (CBC / cirrhosis) in adults
Evidence-based recommendations on ocrelizumab (Ocrevus) for treating relapsing–remitting multiple sclerosis (MS) in adults
Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults
Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults
Evidence-based recommendations on Holoclar for treating limbal stem cell deficiency in adults after eye burns
Evidence-based recommendations on using Intrabeam radiotherapy during breast-conserving surgery for adults with early breast cancer
Evidence-based recommendations on sofosbuvir–velpatasvir–voxilaprevir (Vosevi) for treating chronic hepatitis C (HCV) in adults
NICE is unable to make a recommendation about the use in the NHS of bezlotoxumab (Zinplava) for preventing recurrent Clostridium difficile infection in adults
NICE is unable to make a recommendation about the use in the NHS of lenalidomide (Revlimid) with bortezomib and dexamethasone for untreated multiple myeloma
NICE is unable to make a recommendation about the use in the NHS of pomalidomide (Imnovid) with bortezomib and dexamethasone for relapsed or refractory myeloma
NICE is unable to make a recommendation about the use in the NHS of brentuximab vedotin (Adcetris) for untreated advanced Hodgkin lymphoma in adults
NICE is unable to make a recommendation about the use in the NHS of bosutinib for untreated chronic myeloid leukaemia because no evidence submission was
NICE is unable to make a recommendation about the use in the NHS of dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive
NICE is unable to make a recommendation on abatacept (Orencia) for treating psoriatic arthritis after DMARDs in adults because of no evidence submission from
NICE is unable to make a recommendation about the use in the NHS of pembrolizumab (Keytruda) for treating recurrent or metastatic squamous cell carcinoma of the
NICE is unable to make a recommendation about the use in the NHS of cabozantinib (Cometriq) for previously treated advanced hepatocellular carcinoma in adults
NICE is unable to make a recommendation about the use in the NHS of denosumab for preventing skeletal-related events in multiple myeloma because no evidence
NICE is unable to make a recommendation about the use in the NHS of decitabine for untreated acute myeloid leukaemia because no evidence submission was
Evidence-based recommendations on lanadelumab (Takhzyro) for preventing recurrent attacks of hereditary angioedema in people aged 12 and over
Evidence-based recommendations on lenalidomide (Revlimid) for the treatment of multiple myeloma in people who have received at least 2 prior therapies
Evidence-based recommendations on dapagliflozin (Forxiga) in combination therapy for treating type 2 diabetes in adults
NICE was unable to make a recommendation about the use in the NHS of tenofovir alafenamide for treating chronic hepatitis B because no evidence submission was
NICE was unable to make a recommendation about the use in the NHS of elotuzumab for previously treated multiple myeloma because no evidence submission was
NICE is unable to make a recommendation about the use in the NHS of alectinib for anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Evidence-based recommendations on ixekizumab (Taltz) for moderate to severe plaque psoriasis in adults
NICE is unable to recommend the use in the NHS of panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer..
Evidence-based recommendations on raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Evidence-based recommendations on pemetrexed disodium (Alimta) for the maintenance treatment of non-small-cell lung cancer (NSCLC)
NICE is unable to make a recommendation about the use in the NHS of afatinib for advanced squamous non-small-cell lung cancer after platinum-based chemotherapy
Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma in adults not previously treated with ipilimumab
Evidence-based recommendations on lenalidomide (Revlimid) for myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults
Evidence-based recommendations on eltrombopag (Revolade) for treating chronic immune (idiopathic) thrombocytopenic purpura (chronic ITP)